Journal of the American College of Cardiology
-
J. Am. Coll. Cardiol. · Oct 2003
Randomized Controlled Trial Multicenter Study Clinical TrialPercutaneous coronary intervention for cardiogenic shock in the SHOCK trial.
We examined the clinical, angiographic, and procedural characteristics determining survival after percutaneous coronary intervention (PCI) for cardiogenic shock. ⋯ Restoration of coronary blood flow is a major predictor of survival in cardiogenic shock. Benefit appears to extend beyond the generally accepted 12-h post-infarction window. Surgery should be considered in shock patients with severe mitral insufficiency or multivessel disease not amenable to relatively complete percutaneous revascularization.
-
J. Am. Coll. Cardiol. · Sep 2003
Randomized Controlled Trial Clinical TrialGlucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial.
In this study we considered the question of whether adjunction of glucose-insulin-potassium (GIK) infusion to primary coronary transluminal angioplasty (PTCA) is effective in patients with an acute myocardial infarction (MI). ⋯ Glucose-insulin-potassium infusion as adjunctive therapy to PTCA in acute MI did not result in a significant mortality reduction in all patients. In the subgroup of 856 patients without signs of HF, a significant reduction was seen. The effect of GIK infusion in patients with signs of HF (Killip class > or =2) at admission is uncertain.
-
J. Am. Coll. Cardiol. · Sep 2003
Randomized Controlled Trial Multicenter Study Clinical TrialA randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis.
This study examined the effect of aspirin on the risk of embolic events in infective endocarditis (IE). ⋯ In endocarditis patients already receiving antibiotic treatment, the addition of aspirin does not appear to reduce the risk of embolic events and is likely associated with an increased risk of bleeding. Aspirin is not indicated in the early management of patients with IE.
-
J. Am. Coll. Cardiol. · Jun 2003
Randomized Controlled Trial Multicenter Study Clinical TrialBeraprost therapy for pulmonary arterial hypertension.
The purpose of this study was to assess the safety and efficacy of the oral prostacyclin analogue beraprost sodium during a 12-month double-blind, randomized, placebo-controlled trial in patients with pulmonary arterial hypertension (PAH). ⋯ These data suggest that beneficial effects may occur during early phases of treatment with beraprost in WHO functional class II or III patients but that this effect attenuates with time.
-
J. Am. Coll. Cardiol. · May 2003
Randomized Controlled Trial Multicenter Study Comparative Study Clinical TrialRandomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study.
This study was designed to compare two treatment strategies in patients with atrial fibrillation(AF): rhythm-control (restoration and maintenance of sinus rhythm) and rate-control (pharmacologic or invasive rate-control and anticoagulation). ⋯ The STAF pilot study showed no differences between the two treatment strategies in all end points except hospitalizations. These data suggest that there was no benefit in attempting rhythm-control in these patients with a high risk of arrhythmia recurrence. It remains unclear whether the results in the rhythm-control group would have been better if sinus rhythm had been maintained in a higher proportion of patients, as all but one end point occurred during AF.